ERBB2 and breast cancer: We found that patients with low expression of KRT19 were significantly correlated with poor prognosis in breast cancer (BC), ER+_, HER2+_, and luminal A_BC patients (Figure 1C), suggesting that KRT19 is downregulated in breast cancer and is significantly correlated with poor breast cancer prognosis.